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Abstract 
Background: Our primary objective was to describe parotid recurrence rates after 
superficial and total parotidectomy. 
Methods: A retrospective cohort study was performed on patients with cutaneous 
melanoma metastatic to the parotid gland who underwent parotidectomy from 1998 
through 2014. Primary outcome was parotid bed recurrence. Secondary outcomes were 
facial nerve function postoperatively and at last follow-up.  
Results: 129 patients were included in the study. Thirty-four (26%) underwent total, 
ninety-five underwent superficial parotidectomy. Twelve (13%) patients developed 
parotid bed recurrence after superficial parotidectomy alone versus zero after total 
(p=0.035). Facial nerve function, clinically detected disease, stage, and adjuvant 
treatment were not statistically different between groups (p=0.32, 0.32, 0.13, 1, 
respectively).  
Conclusion: Parotid bed melanoma recurrence was more common after superficial 
parotidectomy compared to total parotidectomy and recurrence resulted in significant 
facial nerve functional deficit. Our results support total parotidectomy when metastatic 
melanoma involves the parotid nodal basin.  
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Introduction 
 Over 144,860 new cases of melanoma, over 76,000 of which are invasive, will be 
diagnosed in the United States in 2016
1
. Living with melanoma is common with over 1.2 
million melanoma survivors estimated in the United States alone. It is the 3
rd
 most 
prevalent cancer in men and 5
th
 most prevalent cancer in women in the United States
2
. 
Hence, quality of life after treatment is a valid consideration. 
While metastasis to the parotid gland is less common than to the cervical 
lymphatics, parotid lymphatic management is crucial as progression of parotid disease 
places facial nerve function at risk. The lymphatic system develops prior to the formation 
of the parotid capsule; therefore, lymph nodes are incorporated into the parotid 
parenchyma and without regard to facial nerve anatomy, as the facial nerve does not 
represent a fascial boundary to the lymphatic system
3,4
.  
Cadaveric studies have demonstrated that lymph nodes are consistently present 
both superficial and deep to the facial nerve within the parotid gland
5-7
. When total 
parotidectomy has been performed for metastatic melanoma and other parotid 
malignancy, metastatic disease has been found in lymph nodes deep to the facial 
nerve
4,8,9
. For metastatic melanoma, a 7% parotid bed recurrence rate after superficial 
parotidectomy is quoted in the literature
10
, compared with a 0% parotid bed recurrence 
rate after total parotidectomy
8
.  
Despite the evidence that melanoma does metastasize to the deep lobe of the 
parotid gland and that parotid bed recurrence may be reduced with total parotidectomy, 
superficial parotidectomy alone is the recommended treatment in the current National 
Comprehensive Cancer Network (NCCN) guidelines
11
. While studies have reported 
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recurrence rates after superficial or total parotidectomy, no study has directly compared 
recurrence rates after these two surgeries. 
Our primary purpose was to describe parotid bed recurrence rates after superficial 
and total parotidectomy for stage III metastatic melanoma. The secondary aim was to 
describe facial nerve function immediately postoperatively and at last follow up. 
Materials and Methods 
 Approval for this study was granted by the University of Michigan Medical 
School Institutional Review Board for Human Subject Research (HUM00048768). Our 
melanoma database was queried for patients diagnosed with primary cutaneous 
melanoma on the head and neck or melanoma metastatic to the parotid gland with 
unknown primary who underwent initial parotidectomy, either superficial or total, from 
1998 through 2014.  Patients were included in the study if they had biopsy-confirmed 
metastatic melanoma to their parotid gland either on fine-needle aspiration (FNA) 
(performed when a palpable mass was detected on physical examination) or sentinel 
lymph node biopsy (SLNB) (occult nodal disease). Primary excision, SLNB, and/or other 
prior excision of primary site may have been done at another institution and was not an 
exclusion criterion, however all parotidectomies were performed at the University of 
Michigan by surgeons who were members of the University of Michigan 
Multidisciplinary Melanoma Tumor board and regularly treated cutaneous malignancy, 
and/or otolaryngologists with head and neck surgery fellowship training.   
Total parotidectomy was defined as removal of parotid tissue deep to the facial 
nerve in addition to removing gland superficial to the facial nerve. Typically, superficial 
parotidectomy, tracing each branch of the facial nerve, was performed first. Once 
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superficial parotidectomy was complete, parotid tissue deep to the facial nerve was 
removed by carefully dissecting glandular tissue free of the overlying facial nerve. The 
procedure was altered as needed if there was clinically detected disease in both the 
superficial and deep lobe, preventing superficial and deep parotid tissue from being 
removed separately while removing the tumor en-bloc. 
The decision to perform total parotidectomy was surgeon dependent. One of our 
surgeons, Dr. McLean, underwent a practice shift and began performing total 
parotidectomy on all patients with melanoma metastatic to the parotid gland in 2013. The 
remainder of surgeons performed total parotidectomy when there was concern for 
metastatic disease deep to the facial nerve. For these surgeons, the decision to perform 
total parotidectomy was made preoperatively or intraoperatively depending on if there 
was preoperative imaging or intraoperative findings suggestive of possible disease deep 
to the facial nerve. 
Demographics and clinical course/outcome measures were confirmed via the 
electronic medical record by manual abstraction. Interventions compared were superficial 
and total parotidectomy, which was determined by review of the surgeon’s operative 
report. Primary outcome was parotid bed recurrence, confirmed by biopsy in all cases 
except one confirmed with imaging. Variables were clinically detected versus occult 
nodal disease, stage, adjuvant treatment and length of follow up. All patients were 
pathologically staged using the American Joint Committee on Cancer (AJCC) cancer 7
th
 
edition staging criteria
12
. Chemotherapy, immunotherapy, and radiation were all 
considered adjuvant treatment. Adjuvant treatment had to occur after surgery and prior to 
any recurrence to be included in this study. 
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Secondary outcomes were facial nerve function postoperatively and at last follow-
up. Facial nerve function was classified as House-Brackmann 1-3 or 4-6
13
. Inpatient and 
outpatient postoperative notes were reviewed to identify postoperative facial nerve 
function and postoperative complications. Temporary facial asymmetry with full 
recovery of function was categorized based on worst deficit. If facial nerve exam was not 
documented postoperatively then the patient was excluded from analyses of facial nerve 
function. Only complications due to parotidectomy or general anesthesia were included. 
Complications due to neck dissection, such as cranial nerve XI injury, were not included 
when calculating complication rates. Complications occurring during admission and after 
discharge within the first 3 months postoperatively were included. 
Statistical analyses were performed using excel and SPSS version 23 ( IBM, 
New York, USA). Fisher exact tests (for categorical variables) and Mann-Whitney U 
tests (for continuous variables) were used to assess statistically significant differences 
between patients undergoing superficial and total parotidectomy. Log-rank survival 
analysis was performed for parotid recurrence. A p-value of 0.05 was considered 
statistically significant. 
Results 
One hundred twenty-nine patients underwent parotidectomy for metastatic 
melanoma. Thirty-four (26%) underwent total, 95 (74%) underwent superficial 
parotidectomy. Median follow up was 22 months. See Table 1 for additional 
demographic data. Twelve (13%) patients developed parotid bed recurrence after 
superficial parotidectomy versus zero after total parotidectomy (Fisher exact test p = 
0.035; Table 1). Survival analysis, censoring patients lost to follow up, showed no 
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statistically significant difference between interventions (p = 0.10; Figure 1).  
Of the patients that recurred in the parotid bed, 3 (25%) had clinically detected 
(palpable) disease prior to superficial parotidectomy. 33% had stage IIIa disease, 17% 
stage IIIb, and 50% stage IIIc. 25% had adjuvant treatment prior to parotid bed 
recurrence including radiation (1), interferon (1), and combination immune and 
chemotherapy (1).  Primary tumor characteristics, nodal disease burden, and adjuvant 
treatment were compared between patient who did and did not recur after superficial 
parotidectomy (Table 2). There were no significant differences in primary tumor 
characteristics or adjuvant treatment. The only significant difference was in rate of N3 
nodal disease (p = 0.03; Table 2).   
Facial nerve function, complication rate, clinically detected versus occult nodal 
disease, stage, and if adjuvant treatment was administered were not statistically different 
between groups (Table 1). When the type of adjuvant treatment was examined, 
significantly more patients who underwent superficial parotidectomy underwent adjuvant 
immune therapy with interferon (Table 1). The rate of radiation therapy, chemotherapy, 
and combined modality therapy was not significantly different between groups (Table 1). 
Interferon was the only immune therapy patients in this study received.  
The average length of follow up in the superficial parotidectomy group was 
shorter than the total parotidectomy group (24 months vs. 16 months, p = 0.05; Table 1), 
which is at least partially due to more total parotidectomies performed in 2013 and 2014.  
Twenty-five patients who underwent superficial parotidectomy had no 
postoperative facial nerve function documented and were therefore excluded from facial 
nerve function analyses. Two patients were House-Brackmann (HB) 4 or greater in the 
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early postoperative period after superficial parotidectomy. Neither was due to 
intraoperatively-documented tumor on or surrounding the facial nerve. One regained 
complete eye closure over the first 6 months of follow up. The other had no documented 
improvement in facial nerve function throughout their follow up. Four patients were HB 
4 or greater in the early postoperative period after total parotidectomy. All four were due 
to tumor encasement of the facial nerve with intraoperative sacrifice of the upper division 
(2) or main trunk (2). One of these patients was excluded from facial nerve function 
analyses because they presented preoperatively, prior to initial parotidectomy, with facial 
paralysis. See Table 1 for complete postoperative facial nerve function results. Of the 12 
patients who had parotid bed recurrence, 10 had facial nerve function documented after 
recurrence, 5 of which developed complete facial nerve paralysis due to recurrent 
melanoma.  
Complications in the total parotidectomy group were: delayed wound healing (1), 
rhabdomyolysis without sequelae (1), and fall with radius fracture (1). Complications in 
the superficial parotidectomy group were: seroma or hematoma (3), delayed wound 
healing (2), urinary tract infection (2), pneumonia (1), rhabdomyolysis requiring 
temporary hemodialysis (1), and pulmonary edema (1; Table 1). 
Discussion 
Our results show a reduced parotid bed recurrence rate following total 
parotidectomy compared to superficial parotidectomy for metastatic melanoma to the 
parotid gland. Additionally, no increased morbidity was associated with total 
parotidectomy compared to superficial parotidectomy in our cohort. These findings are 
consistent with the single prior report of total parotidectomy for metastatic melanoma, 
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which also showed no recurrences in the parotid bed
8
. Reduced parotid bed recurrence is 
particularly important in the head and neck as optimal control of regional disease and 
patient quality of life are likely linked and clinically significant.  
High-level evidence is lacking to precisely quantify the impact of parotid 
recurrence on quality of life. However, facial nerve function is important to patient 
quality of life and House-Brackmann scores have been inversely related to health-related 
quality of life
14
. It can be inferred that parotid bed recurrence with an associated 42% risk 
of facial paralysis in our cohort negatively impacted patient quality of life.  
Primary tumor characteristics predictive of parotid bed recurrence after superficial 
parotidectomy would assist in selecting patients for total parotidectomy. Unfortunately, 
we were unable to identify any such characteristics in our cohort. Nodal disease burden 
was greater in patients who recurred in their parotid bed after superficial parotidectomy; 
however, this information is usually not known until after parotidectomy is complete, so 
is of limited use in selecting who should undergo total parotidectomy. This is an area 
where additional research could provide more guidance on selecting patients for total 
parotidectomy.  
It is important to carefully consider the potential for additional morbidity 
associated with total versus superficial parotidectomy. Given the more extensive facial 
nerve dissection required for total parotidectomy, postoperative facial nerve function is 
an important endpoint for consideration. Our results showed no increased facial 
asymmetry after total parotidectomy compared to superficial parotidectomy. We 
speculate that total parotidectomy did not result in greater facial nerve injury than 
superficial parotidectomy because the majority of risk to the facial nerve was during main 
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trunk identification and initial dissection to delineate each branch. Deep lobe parotid 
excision usually occurred after all branches of the facial nerve were already clearly 
delineated and required only minimal freeing of parotid gland from the underside of the 
facial nerve. Therefore, there was not significant additional manipulation of the nerve and 
any additional manipulation occurred with all nerve branches fully visualized. Similarly, 
other complication rates were equivalent between the two interventions. These findings 
are consistent with the single previous report of total parotidectomy for melanoma
8
. 
Increased time required for surgery with subsequent longer anesthetic is another 
potential source of morbidity. In our cohort, no increased complication rate was identified 
due to longer surgical time. Still, total parotidectomy does take more time, which may be 
an important consideration especially in patients with high comorbidities. Finally, 
increase  parotid gland removal results in increased soft tissue deficit. This is important 
to discuss preoperatively and may impact patient decision making and expectations. Our 
clinical impression is while a noticeable increase in soft tissue deficit occurs after total 
parotidectomy, the degree is relatively small and cosmetically acceptable by the 
overwhelming majority of patients. 
Our study has limitations which are important to define for optimal design of 
future analyses. Given the retrospective nature of this data set, a definitive causal 
relationship between total parotidectomy and reduced parotid bed recurrence (loss of 
regional control) cannot be established. It is possible other patient or disease 
characteristics account for the difference in recurrence rates observed. However, stage 
and clinically detected versus occult nodal disease were not statistically different between 
interventions.  
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The rate of adjuvant treatment was the same after superficial and total 
parotidectomy. However, there were differences in the type of adjuvant treatment 
received. Specifically, interferon was more often given after superficial parotidectomy 
and radiation after total parotidectomy (Table 1). This may be due to the higher 
percentage of patients with Stage 3C melanoma in the cohort who underwent total 
parotidectomy. The authors do not think that the difference in parotid bed recurrence 
rates is due to this variation in adjuvant treatment because comparison of patients who 
did and did not recur after superficial parotidectomy showed no difference in adjuvant 
treatment rate or type. 
Median length of follow up was shorter in patients who underwent total 
parotidectomy (16 months), so it is possible with longer follow up more recurrences 
would be detected in this group. However, within the superficial parotidectomy group 
50% of the parotid bed recurrences occurred within the first 16 months.  Thus, if the 
interventions had equivalent parotid bed recurrence rates one would expect to see some 
recurrences after total parotidectomy during the follow-up time of this analysis, of which 
we had zero. We intend to continue to study our cohort prospectively to allow for further 
determination of any recurrences and subsequent morbidity.  
The retrospective design also affects uniformity of data. Specifically, facial nerve 
function reporting was variable in presence and quality. However, all patients who 
underwent total parotidectomy had postoperative facial nerve function documented. 
While it is possible that patients without documented facial nerve function may have had 
paresis not included in the analysis, this would serve to increase facial nerve paresis rates 
after superficial parotidectomy, not total parotidectomy. 
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Finally, our data does not address larger questions such as: Does total 
parotidectomy improve disease free survival or overall survival? Our suspicion is that it 
does not, but we believe reduction in parotid bed recurrence, and therefore facial nerve 
paralysis, is compelling enough to consider total parotidectomy over superficial 
parotidectomy for metastatic melanoma in the parotid gland. 
Conclusion 
Parotid bed melanoma recurrence was more common after superficial 
parotidectomy compared to total parotidectomy and recurrence resulted in significant 
facial nerve functional deficit.  Post-operative complications and facial nerve function 
were comparable after superficial and total parotidectomy. Our results support total 
parotidectomy when metastatic melanoma involves the parotid nodal basin. Our data also 
provides a framework for optimal study design in the future to better answer important 
clinical questions pertaining to surgical treatment of parotid metastatic melanoma.  
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 Superficial Parotidectomy 
95 (74) n (%) 
Total Parotidectomy 
34 (26) 
n (%) 
p - value 
Age at diagnosis 60 years 58 years 0.68 
Male 68 (72) 25 (74) 1.00 
Length of follow up 24 months 16 months 0.05 
Stage 3a 31 (33) 8 (24)  
Stage 3b 35 (36) 9 (26)  
Stage 3c 29 (31) 17 (50) 0.13 
Clinically detected 
disease 
40 (42) 18 (53) 
0.32 
Adjuvant treatment 
(all) 
35 (36) 12 (35) 
1.00 
Radiation 10 (11) 8 (24) 0.08 
Chemotherapy 0 (0) 1 (3) 0.26 
Immune therapy 23 (24) 2 (6) 0.02 
Combined 2 (2) 1 (3) 1.00 
Facial nerve HB 1-3 68 (97) 30 (91)   
Facial nerve HB 4-6 2 (3) 3 (9) 0.32 
Complications 10 (11) 3 (9) 1.00 
Parotid recurrence 12 (13) [3.4; 6.0-19.3] 0 0.04 
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Table 1. Comparison of variables by intervention (superficial versus total parotidectomy). 
Values shown as N (%) except for age and length of follow up, which are median values. 
For parotid recurrence, standard error (SE) with 95% confidence interval (CI) is shown as 
[SE; 95% CI range]. 25 patients who underwent superficial parotidectomy did not have 
facial nerve function documented. 1 patient who underwent total parotidectomy presented 
prior to surgery with facial paralysis. These 26 patients were excluded from facial nerve 
statistical analyses. HB = House-Brackmann.  
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 Parotid Recurrence 
12 (13) n (%) 
No parotid recurrence 
84 (87) n (%) 
p - value 
Primary location    
Scalp/forehead 6 (50) 27 (34) 0.34 
Temple/periorbital 1 (8) 16 (20) 0.45 
Cheek 4 (33) 16 (20) 0.45 
Ear 0 (0) 17 (22) 0.11 
Nose/lip 1 (8) 0 (0) 0.13 
Neck 0 (0) 3 (4) 1 
Melanoma subtype    
Nodular 3 (30) 22 (31) 1 
Desmoplastic 1 (10) 4 (6) 0.49 
T classification    
T1 5 (41) 13 (17) 0.12 
T2 2 (17) 18 (25) 0.72 
T3 3 (25) 27 (37) 0.53 
T4 2 (17) 15 (21) 1 
Ulceration present 2 (17) 27 (42) 0.12 
N classification    
N1 4 (33) 42 (50) 0.36 
N2 2 (17) 25 (30) 0.5 
N3 6 (50) 17 (20) 0.03 
Clinically detected 4 (33) 36 (43) 0.76 
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disease 
Satellitosis 3 (50) 7 (41) 1 
Adjuvant 
Treatment    
Any 3 (25) 32 (38) 0.53 
Radiation 1 (8) 9 (11) 1 
Interferon 1 (8) 22 (26) 0.28 
 
Table 2. Comparison of variables in patients who did and did not recur after superficial 
parotidectomy. The primary tumor location was unknown in 5 patients who did not recur 
in the parotid bed after superficial parotidectomy. A melanoma subtype was not 
characterized for 14 patients, 12 of which did not recur. The depth of invasion was not 
documented for 11 primary tumors that did not recur. The presence or absence of 
ulceration was not documented in an additional 8 patients who did not recur. All 
percentages and p-values calculated using only cases where this information was 
provided. Satellitosis is defined by AJCC staging guidelines and thus the denominator for 
percentages was total N3 disease. Values shown as N (%).  
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Figure 1. Parotid bed recurrence-free survival. p = 0.10.  
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Figure 1. Parotid bed recurrence-free survival. p = 0.10.  
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